



A34466-A-PCT-USA-A (070050.2532)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fisher et al.
Serial No. : 10/783,571 Authorized Officer: Not Yet Assigned
Filed : February 20, 2004 Group Art Unit: 1614
For : COMBINATORIAL METHODS FOR INDUCING CANCER
CELL DEATH

INFORMATION
DISCLOSURE
STATEMENT

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

May 25, 2005

Date of Deposit

Lisa B. Kole,

Attorney Name

Signature

35,225

PTO Registration No.

May 25, 2005

Date of Signature

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 C.F.R. §1.97 and 1.98, Applicants respectfully
request that the references relating to the above-mentioned application listed herein be
made of record in the U.S. Patent and Trademark Office. The referenced citations are
listed in the accompanying PTO Form 1449 and copies of the references are enclosed.

1. International Patent Application No. PCT/US2003/028512, by Fisher et al., MDA-7 and free radicals in the treatment of cancer. Filed, September 9, 2003 and published on July 22, 2004, under International Publication No. WO 2004/060269.
2. Sarkar et al., 2002. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc. Natl Acad Sci USA 99(15):10054-10059.
3. International Patent Application No. PCT/US01/47215 by Chada et al., for Methods of treatment involving human mda-7. Filed December 7, 2001 and published on June 13, 2002, under International Publication No. WO 02/45737.
4. Cancer Facts and Figures, 2001. Atlanta, GA; American Cancer Society, 2001.
5. Clarke GA, Ryan E, Crowe JP, O'Keane JC, MacMathuna P (2001). Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int. J. Colorectal Dis. 16(2):108-111.
6. Demunter A, Ahmadian MR, Libbrecht L, Stas M, Baens M, Scheffzek K, Degreef H, De Wolf-Peeters C, van Den Oord JJ (2001). A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61(12):4916-4922.
7. Ding XZ, Adrian TE (2001). MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochem. Biophys. Res. Commun. 282(2):447-453.

8. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM (2001). Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. *Cancer Res.* 61(10):4222-4228.
9. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM (2001). TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. *Int. J. Cancer* 93(2):204-211.
10. El-Hariry I, Pignatelli M, Lemoine NR (2001). FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines. *Br. J. Cancer* 84(12):1656-1663.
11. Evans DB, Wolff RA, Crane CH (2001). Neoadjuvant strategies for pancreatic cancer. *Oncology (Huntingt)* 15(6):727-737.
12. Gazdar et al., (2001) "targeted therapies for killing tumor cells", *PNAS* 98: 10028-10030.
13. Glazyrin AL, Adsay VN, Vaitkevicius VK, Sarkar FH (2001). CD95-related apoptotic machinery is functional in pancreatic cancer cells. *Pancreas* 22(4):357-365.
14. Gunzburg WH, Salmons B. (2001). Novel clinical strategies for the treatment of pancreatic carcinoma. *Trends Mol. Med.* 7(1):30-37.

15. Hashimoto K, Nio Y, Sumi S, Toga T, Omori H, Itakura M, Yano S (2001). Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. *Pancreas* 22(4):341-347.
16. Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, Kim SW, Kim WH, Yoon YB, Kim CY (2001). Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. *Cancer Lett.* 169(1):59-68.
17. International Patent Application No. PCT/US00/19392 by Mhashilkar et al. for Methods for treatment of hyperproliferative diseases using human mda-7. Filed July 13,, 2000 and published on January 25, 2001 under International Publication No. WO 01/05437.
18. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS, Fanger G, Stewart L, Watson GJ, Snary D, Fisher PB, Sacki T, Roth JA, Ramesh R, Chada S (2001). Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. *Mol. Med.* 7(4):271-282.
19. Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, Terada M, Yoshida T (2001). Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. *Mol. Ther.* 3(4):491-499.
20. Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T (2001). K-ras gene mutations in non-small cell lung cancer in Japanese. *Oncol. Rep.* 8(4):889-92.

21. Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. *Cancer Res.* 61(11):4405-4413.
22. Perrais M, Pigny P, Ducourouble MP, Petitprez D, Porchet N, Aubert JP, Van Seuning I (2001). Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. *J. Biol. Chem.* 276(33):30923-30933.
23. Rekasi Z, Varga JL, Schally AV, Plonowski A, Halmos G, Csernus B, Armatis P, Groot K (2001). Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways. *Peptides* 22(6):879-886.
24. Sakamoto A, Oda Y, Adachi T, Oshiro Y, Tamiya S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M (2001). H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis. *Mod. Pathol.* 14(4):343-349.
25. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP (2001). 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. *J. Cell. Biochem.* 82(1):110-122.
26. Sherman WH, Fine RL (2001). Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. *Oncology* 60(4):316-321.

27. Su et al., (2001) "A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells", PNAS 98: 10332-10337.
28. Tanaka M, Inase N, Miyake S, Yoshizawa Y (2001). Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anticancer Res. 21(1A):291-294.
29. United States Patent No. 6,255,071 by Beach et al., issued July 3, 2001. Mammalian viral vectors and their uses.
30. United States Patent No. 6,255,111 by Bennett et al., issued July 3, 2001. Antisense modulation of Her-4 expression.
31. United States Patent No. 6,245,747 by Porter et al., issued June 12, 2001. Targeted site specific antisense oligodeoxynucleotide delivery method.
32. United States Patent No. 6,245,520 by Wang et al., issued June 12, 2001. Methods for introducing nucleic acids into mammalian cells using imidazolium lipids.
33. United States Patent No. 6,242,589 by Cook et al., issued June 5, 2001. Phosphorothioate oligonucleotides having modified internucleoside linkages.
34. United States Patent No. 6,235,310 by Wang et al., issued May 22, 2001. Methods of delivery using cationic lipids and helper lipids.
35. United States Patent No. 6,229,006 by Wu, issued May 8, 2001. Use of antisense oligodeoxynucleotides to produce truncated proteins.
36. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A (2001). Frequent k-ras-2 mutations and p16(INK4A) methylation in

- hepatocellular carcinomas in workers exposed to vinyl chloride. *Br. J. Cancer* 84(7):982-989.
37. Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, Spencer DM (2001). Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. *Human Gene Ther.* 12(5):549-61.
38. Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT (2000). Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. *Cancer Res.* 60(16):4305-4310.
39. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000). Comparison of potential markers of farnesyltransferase inhibition. *Clin. Cancer Res.* 6(6):2318-2325.
40. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH (2000). Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. *J. Cell Biol.* 149(3):741-754.
41. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F (2000). N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. *Thyroid* 10(1):19-23.
42. Crespo P, León J (2000). Ras proteins in the control of the cell cycle and cell differentiation. *Cell. Mol. Life Sci.* 57(11):1613-1636.

43. Curran MA, Kaiser SM, Achacoso PL, Nolan GP (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. *Mol. Ther.* 1(1):31-38.
44. Eggerding FA (2000). Fluorescent oligonucleotide ligation technology for identification of ras oncogene mutations. *Mol. Biotechnol.* 14(3):223-233.
45. Garcia JM, Gonzalez R, Silva JM, Dominguez G, Vegazo IS, Gamallo C, Provencio M, Espana P, Bonilla F (2000). Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. *Br. J. Cancer* 82(6):1183-1185.
46. Giehl K, Seidel B, Gierschik P, Adler G, Menke A (2000). TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. *Oncogene* 19(39):4531-4541.
47. Gire V, Marshall C, Wynford-Thomas D (2000). PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. *Oncogene* 19(19):2269-2276.
48. Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y (2000). Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. *Int. J. Cancer* 85(5):716-719.
49. Kolch W (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. *Biochem. J.* 351(Pt 2):289-305.

50. Komata et al., (2000) "Combination therapy of malignant glioma cells with 2-5A antisense telomerase RNA and recombinant adenovirus p53", *Gene Ther.* 7(24): 2071-2079.
51. Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebt SM, Lubet RA, You M (2000). Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Carcinogenesis* 21(1):113-116.
52. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA (2000). Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. *Cancer Res.* 60(21):6052-6060.
53. Lorenz M, Heinrich S, Staib-Sebler E, Kohne CH, Wils J, Nordlinger B, Encke A (2000). Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant. *Eur. J. Cancer* 36(8):957-965.
54. Madireddi MT, Su ZZ, Young CS, Goldstein NI, Fisher PB (2000). Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. *Adv. Exptl. Med. Biol.* 465:239-261.
55. Nakao M, Janssen JW, Seriu T, Bartram CR (2000). Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. *Leukemia* 14(2):312-315.
56. O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD (2000). Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. *Prostate* 45(2):149-157.

57. Park JS, Qiao L, Gilfor D, Yang MY, Hylemon PB, Benz C, Darlington G, Firestone G, Fisher PB, Dent P (2000). A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes. *Mol. Biol. Cell.* 11(9):2915-2932.
58. Pawlak W, Zolnieriek J, Sarosiek T, Szczyluk C (2000). Antisense therapy in cancer. *Cancer Treat. Rev.* 26(5):333-350.
59. Reed JC (2000). Mechanisms of apoptosis. *Am. J. Pathol.* 157(5):1415-1430.
60. Reuther GW, Der CJ (2000). The Ras branch of small GTPases: Ras family members don't fall far from the tree. *Curr. Opin. Cell Biol.* 12(2):157-165.
61. Rosenberg L (2000). Pancreatic cancer: a review of emerging therapies. *Drugs* 59(5):1071-1089.
62. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R (2000). Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. *Gene Ther.* 7(23):2051-2057.
63. Schlitzer M, Sattler I (2000). Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors. *Eur J Med Chem* 35(7-8):721-726.
64. Somia N, Verma IM (2000). Gene therapy: trials and tribulations. *Nat. Rev. Genet.* 1(2):91-99.
65. Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N (2000). The dominant negative H-ras mutant,

- N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. *Gene Ther.* 7(6):518-526.
66. United States Patent No. 6,025,192 by Beach et al., issued February 15, 2000. Modified retroviral vectors.
67. Watanabe T, Sakamoto A, Tamiya S, Oda Y, Masuda K, Tsuneyoshi M (2000). H-ras-1 point mutation in malignant peripheral nerve sheath tumors: polymerase chain reaction restriction fragment length polymorphism analysis and direct sequencing from paraffin-embedded tissues. *Int. J. Mol. Med.* 5(6):605-608.
68. Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. *Proc. Natl. Acad. Sci. U.S.A.* 96(6): 2988-2993.
69. Connelly S (1999). Adenoviral vectors for liver-directed gene therapy. *Curr. Opin. Mol. Ther.* 1(5):565-572.
70. Friess H, Kleeff J, Korc M, Buchler MW (1999). Molecular aspects of pancreatic cancer and future perspectives. *Dig. Surg.* 16(4):281-290.
71. Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, Jarman M (1999). Inhibition of protein prenylation by metabolites of limonene. *Biochem. Pharm.* 57(7):801-809.
72. Hilgers W, Kern SE (1999). Molecular genetic basis of pancreatic adenocarcinoma. *Genes Chromosomes Cancer* 26(1):1-12.

73. International Patent Application No. PCT/US99/07199, Publication No. WO 99/49898, by Fisher, published in English on October 7, 1999. Progression elevated gene-3 and uses thereof.
74. Katabi MM, Chan HL, Karp SE, Batist G (1999). Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. *Human Gene Ther.* 10:155-164.
75. Kita K, Saito S, Morioka CY, Watanabe A (1999). Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. *Intl. J. Cancer* 80(4):553-558.
76. International Patent Application No. PCT/US99/05996, Publication No. WO 99/47709, by Maki et al, published in English on September 23,, 1999. Methods for identifying anticancer agents.
77. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. *Proc. Natl. Acad. Sci. U.S.A.* 96(22):12816-12821.
78. Pan CX, Koeneman KS (1999). A novel tumor-specific gene therapy for bladder cancer. *Med. Hypotheses* 53(2):130-135.
79. Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, Townsend K, Perri S, Mento SJ, Jolly DJ, Chang SM, Schlesinger S, Dubensky TW Jr (1999).

- Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. *Proc. Natl. Acad. Sci. U.S.A.* 96(8):4598-4603.
80. Stackhouse MA, Buchsbaum DJ, Kancharla SR, Grizzle WE, Grimes C, Laffoon K, Pederson LC, Curiel DT (1999). Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. *Cancer Gene Ther.* 6(3):209-219.
81. Varras MN, Sourvinos G, Diakomanolis E, Koumantakis E, Flouris GA, Lekka-Katsouli J, Michalas S, Spandidos DA (1999). Detection and clinical correlations of ras gene mutations in human ovarian tumors. *Oncology* 56(2):89-96.
82. Zhang WW (1999). Development and application of adenoviral vectors for gene therapy of cancer. *Cancer Gene Ther.* 6(2):113-138.
83. Blaszkowsky L (1998). Treatment of advanced and metastatic pancreatic cancer. *Front. Biosci.* 3:E214-E225.
84. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ (1998). Increasing complexity of Ras signaling. *Oncogene* 17(11):1395-1413.
85. Ding et al., (1998) "Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication", *Nucl. Acids Res.* 26(13): 3270-3278.
86. Green DR, Reed JC (1998). Mitochondria and apoptosis. *Science* 281(5381):1309-1312.
87. Hao Y, Zhang J, Lu Y, Yi C, Qian W, Cui J (1998). The role of ras gene mutation in gastric cancer and precancerous lesions. *J. Tongji Med. Univ.* 18(3):141-144.

88. Longnecker DS, Terhune PG (1998). What is the true rate of K-ras mutation in carcinoma of the pancreas? *Pancreas* 17(4):323-324.
89. Miyakis S, Sourvinos G, Spandidos DA (1998). Differential expression and mutation of the ras family genes in human breast cancer. *Biochem. Biophys. Res. Commun.* 251(2):609-612.
90. Olsen JC (1998). Gene transfer vectors derived from equine infectious anemia virus. *Gene Ther.* 5(11):1481-1487.
91. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP (1998). The molecular and cellular biology of pancreatic cancer. *Crit. Rev. Eukaryotic Gene Express.* 8(3-4):377-393.
92. Regine WF, John WJ, Mohiuddin M (1998). Adjuvant therapy for pancreatic cancer: current status. *Front. Biosci.* 3:E186-E192.
93. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, Goldstein NI, Fisher PB (1998). The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. *Proc. Natl. Acad. Sci. U.S.A.* 95(24):14400-14405.
94. United States Patent No. 5,719,262 by Buchardt et al., issued February 11, 1998. Peptide nucleic acids having amino acid side chains.
95. United States Patent No. 5,714,331 by Buchardt et al., issued February 3, 1998. Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility.

96. United States Patent No. 5,710,137 by Fisher, issued January 20, 1998. Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype.
97. Advani et al., (1997) Radiogenic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. *Semin Oncol.* 24(6): 633-638.
98. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M (1997). Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. *Mol. Carcinogen.* 20(2):251-258.
99. Grendys EC Jr, Barnes WA, Weitzel J, Sparkowski J, Schlegel R (1997). Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma. *Gynecol. Oncol.* 65(2):343-347.
100. Maltzman TH, Mueller BA, Schroeder J, Rutledge JC, Patterson K, Preston-Martin S, Faustman EM (1997). Ras oncogene mutations in childhood brain tumors. *Cancer Epidemiol. Biomarkers Prev.* 6(4):239-243.
101. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M (1997). Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science* 275(5302):967-969.
102. Saito S, Hata M, Fukuyama R, Sakai K, Kudoh J, Tazaki H, Shimizu N (1997). Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. *Int. J. Urol.* 4(2):178-185.

103. Takakuwa K, Fujita K, Kikuchi A, Sugaya S, Yahata T, Aida H, Kurabayashi T, Hasegawa I, Tanaka K (1997). Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. *Jpn. J. Cancer Res.* 88(2):166-175.
104. Boyce FM, Bucher NL (1996). Baculovirus-mediated gene transfer into mammalian cells. *Proc. Natl. Acad. Sci. U.S.A.* 93(6):2348-2352.
105. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB (1996). The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. *Proc. Natl. Acad. Sci. U.S.A.* 93(17):9160-9165.
106. Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M (1996). Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors. *Gastroenterol.* 111(5):1241-1251.
107. Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N (1996). Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. *J. Surg. Res.* 66(2):125-130.
108. Stein CA (1996). Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. *Trends Biotechnol.* 14(5):147-149.
109. Strayer DS, Milano J (1996). SV40 mediates stable gene transfer in vivo. *Gene Ther.* 3(7):581-587.

110. United States Patent No. 5,539,082 by Nielsen et al., issued July 23, 1996.
Peptide nucleic acids.
111. United States Patent No. 5,543,327 by Yen-Maguire et al., issued August 6, 1996.
112. Aoki K, Yoshida T, Sugimura T, Terada M (1995). Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. *Cancer Res.* 55(17):3810-3816.
113. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. *Gene Ther.* 2(2):107-115.
114. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S (1995). Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. *Cancer Res.* 55(14):3105-3109.
115. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (1995). Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. *Oncogene* 11(12):2477-2486.
116. Lebowitz PF, Davide JP, Prendergast GC (1995). Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. *Mol Cell Biol* 15(12):6613-6622.

117. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. *J. Exp. Med.* 182(5):1545-1556.
118. Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, Imanishi T, Yamazaki J, Takahashi T (1995). Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. *Anticancer Drugs* 6(4):553-561.
119. Su ZZ, Lin J, Prewett M, Goldstein NI, Fisher PB (1995). Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells. *Anticancer Res.* 15:1841-1848.
120. Su ZZ; Yemul S; Estabrook A; Friedman RM; Zimmer SG; Fisher PB (1995). Transcriptional switching model for the regulation of tumorigenesis and metastasis by the Ha-ras oncogene: transcriptional changes in the Ha-ras tumor suppressor gene lysyl oxidase. *Intl. J. Oncol.* 7(6):1279-1284.
121. Bett AJ, Haddara W, Prevec L, Graham FL (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. *Proc. Natl. Acad. Sci. U.S.A.* 91(19):8802-8806.
122. Falck-Pedersen E, Heinflink M, Alvira M, Nussenzveig DR, Gershengorn MC (1994). Expression of thyrotropin-releasing hormone receptors by adenovirus-

mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. *Mol. Pharmacol.* 45(4):684-689.

123. Hayashi Y, DePaoli AM, Burant CF, Refetoff S (1994). Expression of a thyroid hormone-responsive recombinant gene introduced into adult mice livers by replication-defective adenovirus can be regulated by endogenous thyroid hormone receptor. *J. Biol. Chem.* 269(39):23872-23875.
124. Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, et al. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. *Proc. Natl. Acad. Sci. U.S.A.* 91(19):9141-9145.
125. Rossi JJ (1994). Practical ribozymes. Making ribozymes work in cells. *Curr. Biol.* 4(5):469-471.
126. Jiang H, Fisher PB (1993). A sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. *Mol. Cell. Different.* 1(3):285-299.
127. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993). Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. *Science* 260(5116):1934-1937.

128. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL (1993).
Assessment of recombinant adenoviral vectors for hepatic gene therapy. *Hum. Gene Ther.* 4(4):403-409.
129. Mastrangeli A, Danel C, Rosenfeld MA, Stratford-Perricaudet L, Perricaudet M, Pavirani A, Lecocq JP, Crystal RG (1993). Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. *J. Clin. Invest.* 91(1):225-234.
130. Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartaud J, Briand P, Kaplan JC, Perricaudet M, et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. *Nature* 361(6413):647-650.
131. Stein CA, Cheng YC (1993). Antisense oligonucleotides as therapeutic agents--is the bullet really magical? *Science* 261(5124):1004-1012.
132. Dent P, Haser W, Haystead TA, Vincent LA, Roberts TM, Sturgill TW (1992). Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. *Science* 257(5075):1404-1407.
133. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J. Cell Biol.* 119(3):493-501.
134. Helene C, Thuong NT, Harel-Bellan A (1992). Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy. *Ann. N.Y. Acad. Sci.* 660:27-36.

135. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, Gant TW, Thorgeirsson SS, Stratford-Perricaudet LD, Perricaudet M, et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. *Nat. Gen.* 1(5):372-378.
136. Legendre JY, Szoka FC Jr. (1992). Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. *Pharmaceutical Research* 9(10):1235-1242.
137. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G (1992). Ki-ras oncogene activation in preinvasive pancreatic cancer. *Gastroenterol.* 102(1):230-236.
138. Maher LJ 3rd. (1992). DNA triple-helix formation: an approach to artificial gene repressors? *Bioessays* 14(12):807-815.
139. Ozaki H (1992). Improvement of pancreatic cancer treatment from the Japanese experience in the 1980s. *Int. J. Pancreatol.* 12(1):5-9.
140. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL (1992). Adenovirus as an expression vector in muscle cells in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 89(7):2581-2584.
141. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. *Cell* 68(1):143-155.

142. Sutter G, Moss B (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc. Natl. Acad. Sci. U.S.A.* 89(22):10847-10851.
143. Tanaka K, Takechi M, Asaoku H, Dohy H, Kamada N (1992). A high frequency of N-RAS oncogene mutations in multiple myeloma. *Int. J. Hematol.* 56(2):119-127.
144. United States Patent No. 5,093,246 by Cech et al., issued March 3, 1992. RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
145. Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ (1992). Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. *Proc. Natl. Acad. Sci. U.S.A.* 89(15):7257-7261.
146. Warshaw AL, Fernandez-del Castillo C (1992). Pancreatic carcinoma. *N. Engl. J. Med.* 326(7):455-465.
147. Helene C (1991). The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. *Anticancer Drug. Des.* 6(6):569-584.
148. Marion MJ, Froment O, Trepo C (1991). Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. *Mol. Carcinog.* 4(6):450-454.
149. Nielsen PE, Egholm M, Berg RH, Buchardt O. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science* 254(5037):1497-1500.

150. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, et al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. *Science* 252(5004):431-434.
151. Wang Q, Konan V, Taylor MW (1991). Expression of the APRT gene in an adenovirus vector system as a model for studying gene therapy. *Adv. Exp. Med. Biol.* 309B:61-66.
152. Wu GY, Wu CH (1991). Delivery systems for gene therapy. *Biotherapy* 3(1):87-95.
153. Arbuck SG (1990). Overview of chemotherapy for pancreatic cancer. *Int. J. Pancreatol.* 7(1-3):209-222.
154. Cohn I Jr. (1990). Overview of pancreatic cancer, 1989. *Int. J. Pancreatol.* 7(1-3):1-11.
155. Geller AI, Freese A (1990). Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. *Proc. Natl. Acad. Sci. U.S.A.* 87(3):1149-1153.
156. Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. *Human Gene Ther.* 1(3):241-256.

157. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990). Direct gene transfer into mouse muscle in vivo. *Science* 247(4949 Pt1):1465-1468.
158. Ausubel et al. (1989). *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc. New York, at p. 2.10.3.
159. Miller AD, Rosman GJ (1989). Improved retroviral vectors for gene transfer and expression. *Biotechniques* 7(9):981-990.
160. Yamaguchi K, Enjoji M (1989). Carcinoma of the pancreas: a clinicopathologic study of 96 cases with immunohistochemical observations. *Jpn. J. Clin. Oncol.* 19(1):14-22.
161. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 53(4):549-554.
162. Berkner KL (1988). Development of adenovirus vectors for the expression of heterologous genes. *Biotechniques* 6(7):616-624.
163. Hambor JE, Hauer CA, Shu HK, Groger RK, Kaplan DR, Tykocinski ML (1988). Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone. *Proc. Natl. Acad. Sci. U.S.A.* 85(11):4010-4014.
164. Haseloff J, Gerlach WL (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. *Nature* 334(6183):585-591.

165. McGrory WJ, Bautista DS, Graham FL (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. *Virology* 163(2):614-617.
166. Nicolau C, Legrand A, Grosse E (1987). Liposomes as carriers for in vivo gene transfer and expression. *Methods in Enzymology* 149:157-176.
167. Been MD, Cech TR (1986). One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. *Cell* 47(2):207-216.
168. Zaug AJ, Cech TR (1986). The intervening sequence RNA of Tetrahymena is an enzyme. *Science* 231(4737):470-475.
169. Zaug AJ, Been MD, Cech TR (1986). The Tetrahymena ribozyme acts like an RNA restriction endonuclease. *Nature* 324(6096):429-433.
170. Zaug AJ, Kent JR, Cech TR (1984). A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA. *Science* 224(4649):574-578.
171. Volkert FC, Young CS (1983). The genetic analysis of recombination using adenovirus overlapping terminal DNA fragments. *Virol.* 125(1):175-193.
172. Graham FL, Smiley J, Russell WC, Nairn R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen. Virol.* 36(1):59-72.


The referenced citations are listed in the accompanying PTO Form 1449 and copies of the references are provided.

Identification of the above-listed references is not to be construed as an admission of the Applicants or the attorneys of the Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-mentioned application.

Please charge our Deposit Account No. 02-4377 if there is any additional fee required. Two copies of this communication are enclosed.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Lisa B. Kole', is written over a horizontal line.

Lisa B. Kole, M.D., Ph.D.

Patent Office Reg. No. 35,225

Attorney for Applicants
(212) 408-2628

Enclosures



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)		Serial No. 10/783,571
	Applicant Fisher <i>et al.</i>		
	Filing Date March 10, 2005		Group 1614
	Examiner To be assigned		

U.S. PATENT DOCUMENTS														
*Exa m. Init.	No.		Document No.						Date	Name	Class	Subclass	Filing Date if Appro.	
	29.		6	2	5	5	0	7	1	July 3, 2001	Beach et al			
	30		6	2	5	5	1	1	1	July 3, 2001	Bennett et al			
	31.		6	2	4	5	7	4	7	June 12, 2001	Poerter et al.			
	32.		6	2	4	5	5	2	0	June 12, 2001	Wang et al.			
	33.		6	2	4	2	5	8	9	June 5, 2001	Cook et al.			
	34.		6	2	3	5	3	1	0	May 22, 2001	Wang et al.			
	35.		6	2	2	9	0	0	6	May 8, 2001	Wu			
	66.		6	0	2	5	1	9	2	Feb. 15, 2000	Beach et al.			
	94.		5	7	1	9	2	6	2	Feb. 11, 1998	Buchardt et al.			
	95.		5	7	1	4	3	3	1	Feb. 3, 1998	Buchardt et al.			
	96.		5	7	1	0	1	3	7	Jan. 20, 1998	Fisher			
	110.		5	5	3	9	0	8	2	July 23, 1996	Nielsen			
	111		5	5	4	3	3	2	7	Aug. 6, 1996	Yen-Maguire			

NY02:511603
Examiner
Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)		Serial No. 10/783,571
	Applicant Fisher <i>et al.</i>		
	Filing Date March 10, 2005		Group 1614
	Examiner To be assigned		

U.S. PATENT DOCUMENTS														
*Exa m. Init.	No.	Document No.							Date	Name	Class	Subclass	Filing Date if Appro.	
	144.		5	0	9	3	2	4	6	Mar. 3, 1992	Cech et al.			

FOREIGN PATENT DOCUMENTS													
	No.	Document No.							Date	Country	Class	Subclass	Translation Yes No
	1	WO 2004/060269							July 22, 2004	WO			
	3	WO 02/45737							June 13, 2002	WO			
	17.	WO 01/05437							Jan. 25, 2001	WO			
	73.	WO 99/49898							Oct 07, 1999	WO			
	76	WO 99/47709							Sept 23, 1999	WO			

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
2.	Sarkar et al., 2002. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK Proc. Natl Acad Sci USA 99(15):10054-10059.
4.	Cancer Facts and Figures, 2001. Atlanta GA. American Cancer Society
5.	Clarke GA, Ryan E, Crowe JP, O'Keane JC, MacMathuna P (2001). Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int. J. Colorectal Dis. 16(2):108-111.
6.	Demunter A, Ahmadian MR, Libbrecht L, Stas M, Baens M, Scheffzek K, Degreef H, De Wolf-Peeters C, van Den Oord JJ (2001). A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61(12):4916-4922.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
7.	Ding XZ, Adrian TE (2001). MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochem. Biophys. Res. Commun. <u>282(2)</u> :447-453.
8.	Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM (2001). Transforming growth factor betal treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. <u>61(10)</u> :4222-4228.
9.	Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM (2001). TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int. J. Cancer <u>93(2)</u> :204-211.
10.	El-Hariry I, Pignatelli M, Lemoine NR (2001). FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines. Br. J. Cancer <u>84(12)</u> :1656-1663.
11.	Evans DB, Wolff RA, Crane CH (2001). Neoadjuvant strategies for pancreatic cancer. Oncology (Huntingt) <u>15(6)</u> :727-737.
12.	Gazdar et al., (2001) "targeted therapies for killing tumor cells", PNAS 98: 10028-10030.
13.	Glazyrin AL, Adsay VN, Vaitkevicius VK, Sarkar FH (2001). CD95-related apoptotic machinery is functional in pancreatic cancer cells. Pancreas <u>22(4)</u> :357-365.
14.	Gunzburg WH, Salmons B. (2001). Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol. Med. <u>7(1)</u> :30-37.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
15.	Hashimoto K, Nio Y, Sumi S, Toga T, Omori H, Itakura M, Yano S (2001). Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. <i>Pancreas</i> <u>22</u> (4):341-347.
16.	Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, Kim SW, Kim WH, Yoon YB, Kim CY (2001). Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. <i>Cancer Lett.</i> <u>169</u> (1):59-68.
18.	Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS, Fanger G, Stewart L, Watson GJ, Snary D, Fisher PB, Saeki T, Roth JA, Ramesh R, Chada S (2001). Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. <i>Mol. Med.</i> <u>7</u> (4):271-282.
19.	Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, Terada M, Yoshida T (2001). Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. <i>Mol. Ther.</i> <u>3</u> (4):491-499.
20.	Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, Shirakusa T (2001). K-ras gene mutations in non-small cell lung cancer in Japanese. <i>Oncol. Rep.</i> <u>8</u> (4):889-92.
21.	Peng XY, Won JH, Rutherford T, Fujii T, Zeltermann D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. <i>Cancer Res.</i> <u>61</u> (11):4405-4413.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
22.	Perrais M, Pigny P, Ducourouble MP, Petitprez D, Porchet N, Aubert JP, Van Seuning I (2001). Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. <i>J. Biol. Chem.</i> <u>276</u> (33):30923-30933.
23.	Rekasi Z, Varga JL, Schally AV, Plonowski A, Halmos G, Csernus B, Armatis P, Groot K (2001). Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways. <i>Peptides</i> <u>22</u> (6):879-886.
24.	Sakamoto A, Oda Y, Adachi T, Oshiro Y, Tamiya S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M (2001). H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis. <i>Mod. Pathol.</i> <u>14</u> (4):343-349.
25.	Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP (2001). 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. <i>J. Cell. Biochem.</i> <u>82</u> (1):110-122.
26.	Sherman WH, Fine RL (2001). Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. <i>Oncology</i> <u>60</u> (4):316-321.
27.	Su et al., (2001) "A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells", <i>PNAS</i> 98: 10332-10337.
28.	Tanaka M, Inase N, Miyake S, Yoshizawa Y (2001). Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. <i>Anticancer Res.</i> <u>21</u> (1A):291-294.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
36.	Weihsrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A (2001). Frequent k-ras-2 mutations and p16(INK4A) methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br. J. Cancer 84(7):982-989.
37.	Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, Spencer DM (2001). Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Human Gene Ther. 12(5):549-61.
38.	Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT (2000). Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res. 60(16):4305-4310.
39.	Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000). Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6(6):2318-2325.
40.	Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH (2000). Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J. Cell Biol. 149(3):741-754.
41.	Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F (2000). N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10(1):19-23.
42.	Crespo P, León J (2000). Ras proteins in the control of the cell cycle and cell differentiation. Cell. Mol. Life Sci. 57(11):1613-1636.
43.	Curran MA, Kaiser SM, Achacoso PL, Nolan GP (2000). Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1(1):31-38.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
44.	Eggerding FA (2000). Fluorescent oligonucleotide ligation technology for identification of ras oncogene mutations. Mol. Biotechnol. <u>14</u> (3):223-233.
45.	Garcia JM, Gonzalez R, Silva JM, Dominguez G, Vegazo IS, Gamallo C, Provencio M, Espana P, Bonilla F (2000). Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. Br. J. Cancer <u>82</u> (6):1183-1185.
46.	Giehl K, Seidel B, Gierschik P, Adler G, Menke A (2000). TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene <u>19</u> (39):4531-4541.
47.	Gire V, Marshall C, Wynford-Thomas D (2000). PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene <u>19</u> (19):2269-2276.
48.	Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y (2000). Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Int. J. Cancer <u>85</u> (5):716-719.
49.	Kolch W (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. <u>351</u> (Pt 2):289-305.
50.	Komata et al., (2000) "Combination therapy of malignant glioma cells with 2-5A antisense telomerase RNA and recombinant adenovirus p53", Gene Ther. <u>7</u> (24): 2071-2079.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	51.	Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M (2000). Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. <i>Carcinogenesis</i> <u>21(1)</u> :113-116.
	52.	Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA (2000). Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. <i>Cancer Res.</i> <u>60(21)</u> :6052-6060.
	53.	Lorenz M, Heinrich S, Staib-Sebler E, Kohne CH, Wils J, Nordlinger B, Encke A (2000). Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant. <i>Eur. J. Cancer</i> <u>36(8)</u> :957-965.
	54.	Madireddi MT, Su ZZ, Young CS, Goldstein NI, Fisher PB (2000). Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. <i>Adv. Exptl. Med. Biol.</i> <u>465</u> :239-261.
	55.	Nakao M, Janssen JW, Seriu T, Bartram CR (2000). Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. <i>Leukemia</i> <u>14(2)</u> :312-315.
	56.	O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD (2000). Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. <i>Prostate</i> <u>45(2)</u> :149-157.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	57.	Park JS, Qiao L, Gilfor D, Yang MY, Hylemon PB, Benz C, Darlington G, Firestone G, Fisher PB, Dent P (2000). A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes. <i>Mol. Biol. Cell.</i> <u>11(9)</u> :2915-2932.
	58.	Pawlak W, Zolnieriek J, Sarosiek T, Szczyluk C (2000). Antisense therapy in cancer. <i>Cancer Treat. Rev.</i> <u>26(5)</u> :333-350.
	59.	Reed JC (2000). Mechanisms of apoptosis. <i>Am. J. Pathol.</i> <u>157(5)</u> :1415-1430.
	60.	Reuther GW, Der CJ (2000). The Ras branch of small GTPases: Ras family members don't fall far from the tree. <i>Curr. Opin. Cell Biol.</i> <u>12(2)</u> :157-165.
	61.	Rosenberg L (2000). Pancreatic cancer: a review of emerging therapies. <i>Drugs</i> <u>59(5)</u> :1071-1089.
	62.	Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R (2000). Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. <i>Gene Ther.</i> <u>7(23)</u> :2051-2057.
	63.	Schlitzer M, Sattler I (2000). Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors. <i>Eur J Med Chem</i> <u>35(7-8)</u> :721-726.
	64.	Somia N, Verma IM (2000). Gene therapy: trials and tribulations. <i>Nat. Rev. Genet.</i> <u>1(2)</u> :91-99.
	65.	Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N (2000). The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. <i>Gene Ther.</i> <u>7(6)</u> :518-526.
NY02:511603		
Examiner	Date Considered	

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
67.	Watanabe T, Sakamoto A, Tamiya S, Oda Y, Masuda K, Tsuneyoshi M (2000). H-ras-1 point mutation in malignant peripheral nerve sheath tumors: polymerase chain reaction restriction fragment length polymorphism analysis and direct sequencing from paraffin-embedded tissues. <i>Int. J. Mol. Med.</i> 5(6):605-608.
68.	Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 96(6): 2988-2993.
69.	Connelly S (1999). Adenoviral vectors for liver-directed gene therapy. <i>Curr. Opin. Mol. Ther.</i> 1(5):565-572.
70.	Friess H, Kleeff J, Korc M, Buchler MW (1999). Molecular aspects of pancreatic cancer and future perspectives. <i>Dig. Surg.</i> 16(4):281-290.
71.	Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, Jarman M (1999). Inhibition of protein prenylation by metabolites of limonene. <i>Biochem. Pharm.</i> 57(7):801-809.
72.	Hilgers W, Kern SE (1999). Molecular genetic basis of pancreatic adenocarcinoma. <i>Genes Chromosomes Cancer</i> 26(1):1-12.
74.	Katabi MM, Chan HL, Karp SE, Batist G (1999). Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. <i>Human Gene Ther.</i> 10:155-164.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
75.	Kita K, Saito S, Morioka CY, Watanabe A (1999). Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Intl. J. Cancer 80(4):553-558.
76.	International Patent Application No. PCT/US99/05996, Publication No. WO 99/47709, by Maki et al, published in English on September 23,, 1999. Methods for identifying anticancer agents
77.	Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Cordova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U.S.A. 96(22):12816-12821.
78.	Pan CX, Koeneman KS (1999). A novel tumor-specific gene therapy for bladder cancer. Med. Hypotheses 53(2):130-135.
79.	Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, Townsend K, Perri S, Mento SJ, Jolly DJ, Chang SM, Schlesinger S, Dubensky TW Jr (1999). Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc. Natl. Acad. Sci. U.S.A. 96(8):4598-4603.
80.	Stackhouse MA, Buchsbaum DJ, Kancharla SR, Grizzle WE, Grimes C, Laffoon K, Pederson LC, Curiel DT (1999). Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Ther. 6(3):209-219.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
81.	Varras MN, Sourvinos G, Diakomanolis E, Koumantakis E, Flouris GA, Lekka-Katsouli J, Michalas S, Spandidos DA (1999). Detection and clinical correlations of ras gene mutations in human ovarian tumors. <i>Oncology</i> 56(2):89-96.
82.	Zhang WW (1999). Development and application of adenoviral vectors for gene therapy of cancer. <i>Cancer Gene Ther.</i> 6(2):113-138.
83.	Blazskowsky L (1998). Treatment of advanced and metastatic pancreatic cancer. <i>Front. Biosci.</i> 3:E214-E225.
84.	Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ (1998). Increasing complexity of Ras signaling. <i>Oncogene</i> 17(11):1395-1413.
85.	Ding et al., (1998) "Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication", <i>Nucl. Acids Res.</i> 26(13): 3270-3278.
86.	Green DR, Reed JC (1998). Mitochondria and apoptosis. <i>Science</i> 281(5381):1309-1312.
87.	Hao Y, Zhang J, Lu Y, Yi C, Qian W, Cui J (1998). The role of ras gene mutation in gastric cancer and precancerous lesions. <i>J. Tongji Med. Univ.</i> 18(3):141-144.
88	Longnecker DS, Terhune PG (1998). What is the true rate of K-ras mutation in carcinoma of the pancreas? <i>Pancreas</i> 17(4):323-324.
89.	Miyakis S, Sourvinos G, Spandidos DA (1998). Differential expression and mutation of the ras family genes in human breast cancer. <i>Biochem. Biophys. Res. Commun.</i> 251(2):609-612.
90.	Olsen JC (1998). Gene transfer vectors derived from equine infectious anemia virus. <i>Gene Ther.</i> 5(11):1481-1487.
NY02:511603	
<div>Examiner</div> <div>Date Considered</div>	

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
91.	Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP (1998). The molecular and cellular biology of pancreatic cancer. Crit. Rev. Eukaryotic Gene Express. 8(3-4):377-393.
92.	Regine WF, John WJ, Mohiuddin M (1998). Adjuvant therapy for pancreatic cancer: current status. Front. Biosci. 3:E186-E192.
93.	Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, Goldstein NI, Fisher PB (1998). The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. U.S.A. 95(24):14400-14405.
97.	Advani et al., (1997) Radiogenic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 24(6): 633-638.
98.	Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M (1997). Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol. Carcinogen. 20(2):251-258.
99.	Grendys EC Jr, Barnes WA, Weitzel J, Sparkowski J, Schlegel R (1997). Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma. Gynecol. Oncol. 65(2):343-347.
100.	Maltzman TH, Mueller BA, Schroeder J, Rutledge JC, Patterson K, Preston-Martin S, Faustman EM (1997). Ras oncogene mutations in childhood brain tumors. Cancer Epidemio. Biomarkers Prev. 6(4):239-243.
101.	Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M (1997). Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275(5302):967-969.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
102.	Saito S, Hata M, Fukuyama R, Sakai K, Kudoh J, Tazaki H, Shimizu N (1997). Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. <i>Int. J. Urol.</i> 4(2):178-185.
103.	Takakuwa K, Fujita K, Kikuchi A, Sugaya S, Yahata T, Aida H, Kurabayashi T, Hasegawa I, Tanaka K (1997). Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. <i>Jpn. J. Cancer Res.</i> 88(2):166-175.
104.	Boyce FM, Bucher NL (1996). Baculovirus-mediated gene transfer into mammalian cells. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93(6):2348-2352.
105.	Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB (1996). The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93(17):9160-9165.
106.	Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M (1996). Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. <i>Gastroenterol.</i> 111(5):1241-1251.
107.	Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N (1996). Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. <i>J. Surg. Res.</i> 66(2):125-130.
108.	Stein CA (1996). Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. <i>Trends Biotechnol.</i> 14(5):147-149.
109.	Strayer DS, Milano J (1996). SV40 mediates stable gene transfer in vivo. <i>Gene Ther.</i> 3(7):581-587.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
112.	Aoki K, Yoshida T, Sugimura T, Terada M (1995). Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. <i>Cancer Res.</i> 55(17):3810-3816.
113.	Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpatei G (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. <i>Gene Ther.</i> 2(2):107-115.
114.	Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S (1995). Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. <i>Cancer Res.</i> 55(14):3105-3109.
115.	Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB (1995). Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. <i>Oncogene</i> 11(12):2477-2486.
116.	Lebowitz PF, Davide JP, Prendergast GC (1995). Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. <i>Mol Cell Biol</i> 15(12):6613-6622.
117.	Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. <i>J. Exp. Med.</i> 182(5):1545-1556.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
118.	Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, Imanishi T, Yamazaki J, Takahashi T (1995). Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. <i>Anticancer Drugs</i> 6(4):553-561.
119.	Su ZZ, Lin J, Prewett M, Goldstein NI, Fisher PB (1995). Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells. <i>Anticancer Res.</i> 15:1841-1848.
120.	Su ZZ; Yemul S; Estabrook A; Friedman RM; Zimmer SG; Fisher PB (1995). Transcriptional switching model for the regulation of tumorigenesis and metastasis by the Ha-ras oncogene: transcriptional changes in the Ha-ras tumor suppressor gene lysyl oxidase. <i>Intl. J. Oncol.</i> 7(6):1279-1284.
121.	Bett AJ, Haddara W, Prevec L, Graham FL (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91(19):8802-8806.
122.	Falck-Pedersen E, Heinfliink M, Alvira M, Nussenzveig DR, Gershengorn MC (1994). Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. <i>Mol. Pharmacol.</i> 45(4):684-689.
123.	Hayashi Y, DePaoli AM, Burant CF, Refetoff S (1994). Expression of a thyroid hormone-responsive recombinant gene introduced into adult mice livers by replication-defective adenovirus can be regulated by endogenous thyroid hormone receptor. <i>J. Biol. Chem.</i> 269(39):23872-23875.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
124.	Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, et al. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. U.S.A.91(19):9141-9145.
125.	Rossi JJ (1994) Practical Ribozymes, Making Ribozymes Work In Cells. Curr. Biol. 4(5): 469-471.
126.	Jiang H, Fisher PB (1993). A sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol. Cell. Different. 1(3):285-299.
127.	Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993). Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260(5116):1934-1937.
128.	Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4(4):403-409.
129.	Mastrangeli A, Danel C, Rosenfeld MA, Stratford-Perricaudet L, Perricaudet M, Pavirani A, Lecocq JP, Crystal RG (1993). Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J. Clin. Invest. 91(1):225-234.
130.	Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartaud J, Briand P, Kaplan JC, Perricaudet M, et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361(6413):647-650.
131.	Stein CA, Cheng YC (1993). Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science 261(5124):1004-1012.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
132.	Dent P, Haser W, Haystead TA, Vincent LA, Roberts TM, Sturgill TW (1992). Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257(5075):1404-1407.
133.	Gavrieli Y, Sherman Y, Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119(3):493-501.
134.	Helene C, Thuong NT, Harel-Bellan A (1992). Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy. Ann. N.Y. Acad. Sci. 660:27-36.
135.	Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, Gant TW, Thorgeirsson SS, Stratford-Perricaudet LD, Perricaudet M, et al. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Gen. 1(5):372-378.
136.	Legendre JY, Szoka FC Jr. (1992). Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharmaceutical Research 9(10):1235-1242.
137.	Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G (1992). Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterol. 102(1):230-236.
138.	Maher LJ 3rd. (1992). DNA triple-helix formation: an approach to artificial gene repressors? Bioessays 14(12):807-815.
139.	Ozaki H (1992). Improvement of pancreatic cancer treatment from the Japanese experience in the 1980s. Int. J. Pancreatol. 12(1):5-9.
140.	Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL (1992). Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 89(7):2581-2584.
NY02:511603	
Examiner _____ Date Considered _____	

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
141.	Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68(1):143-155.
142.	Sutter G, Moss B (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89(22):10847-10851.
143.	Tanaka K, Takechi M, Asaoku H, Dohy H, Kamada N (1992). A high frequency of N-RAS oncogene mutations in multiple myeloma. Int. J. Hematol. 56(2):119-127.
145.	Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ (1992). Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc. Natl. Acad. Sci. U.S.A. 89(15):7257-7261.
146.	Warshaw AL, Fernandez-del Castillo C (1992). Pancreatic carcinoma. N. Engl. J. Med. 326(7):455-465.
147.	Helene C (1991). The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug. Des. 6(6):569-584.
148.	Marion MJ, Froment O, Trepo C (1991). Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol. Carcinog. 4(6):450-454.
149.	Nielsen PE, Egholm M, Berg RH, Buchardt O. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254(5037):1497-1500.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
150.	Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet LD, Perricaudet M, et al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252(5004):431-434.
151.	Wang Q, Konan V, Taylor MW (1991). Expression of the APRT gene in an adenovirus vector system as a model for studying gene therapy. Adv. Exp. Med. Biol. 309B:61-66.
152.	Wu GY, Wu CH (1991). Delivery systems for gene therapy. Biotherapy 3(1):87-95.
153.	Arbuck SG (1990). Overview of chemotherapy for pancreatic cancer. Int. J. Pancreatol. 7(1-3):209-222.
154.	Cohn I Jr. (1990). Overview of pancreatic cancer, 1989. Int. J. Pancreatol. 7(1-3):1-11.
155.	Geller AI, Freese A (1990). Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 87(3):1149-1153.
156.	Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P (1990). Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Human Gene Ther. 1(3):241-256.
157	Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990). Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt1):1465-1468.
158.	Ausubel et al. (1989). Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc. New York, at p. 2.10.1 to 2.10.16 (with page numbers as per Supplement 55, 2001)
NY02:511603	
Examiner _____ Date Considered _____	

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
159.	Miller AD, Rosman GJ (1989). Improved retroviral vectors for gene transfer and expression. <i>Biotechniques</i> 7(9):981-990.
160.	Yamaguchi K, Enjoji M (1989). Carcinoma of the pancreas: a clinicopathologic study of 96 cases with immunohistochemical observations. <i>Jpn. J. Clin. Oncol.</i> 19(1):14-22.
161.	Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. <i>Cell</i> 53(4):549-554.
162.	Berkner KL (1988). Development of adenovirus vectors for the expression of heterologous genes. <i>Biotechniques</i> 6(7):616-624.
163.	Hambor JE, Hauer CA, Shu HK, Groger RK, Kaplan DR, Tykocinski ML (1988). Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 85(11):4010-4014.
164.	Haseloff J, Gerlach WL (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. <i>Nature</i> 334(6183):585-591.
165.	McGrory WJ, Bautista DS, Graham FL (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. <i>Virology</i> 163(2):614-617.
166.	Nicolau C, Legrand A, Grosse E (1987). Liposomes as carriers for in vivo gene transfer and expression. <i>Methods in Enzymology</i> 149:157-176.
167.	Been MD, Cech TR (1986). One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. <i>Cell</i> 47(2):207-216.

NY02:511603	
Examiner	Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466-A-PCT-USA-A (070050.2532)	Serial No. 10/783,571
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher <i>et al.</i>	
	Filing Date March 10, 2005	Group 1614
	Examiner To be assigned	

No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
168.	Zaug AJ, Cech TR (1986). The intervening sequence RNA of Tetrahymena is an enzyme. Science 231(4737):470-475.
169.	Zaug AJ, Been MD, Cech TR (1986). The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 324(6096):429-433.
170.	Zaug AJ, Kent JR, Cech TR (1984). A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA. Science 224(4649):574-578.
171.	Volkert FC, Young CS (1983). The genetic analysis of recombination using adenovirus overlapping terminal DNA fragments. Virol. 125(1):175-193.
172.	Graham FL, Smiley J, Russell WC, Nairn R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36(1):59-72.

NY02:511603

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.